Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Recruiting now · Phase 4

Conditions studied: Multiple Myeloma Refractory, Relapsed Multiple Myeloma

In brief

Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.

Key facts

Study ID

NCT07094048

Run by

CHU de Quebec-Universite Laval

People needed

80

Starts

2026-01-05

Expected to finish

2029-12-01

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple myeloma patient:
• ≥ 18 years old
• ≥ 1 prior lines of therapy
• Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
• On previous Ig support or not

You may not qualify if…

• Less than 18 years old
• Pregancy or breastfeeding

Where it is running

• Santé Québec Chaudière-Appalaches — Lévis, Quebec, Canada (enrolling)
• Centre Intégré de Cancérologie — Québec, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.